Chinook Therapeutics, Inc.
KDNYDelisted Aug 11, 2023- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001435049
Chinook Therapeutics, Inc. was delisted on Aug 11, 2023; its insiders filed their last Form 4 on Aug 11, 2023; 185 institutions reported holding it in 13F filings for Q2 2023, worth $2.24B in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 185
- Q2 2023, +28 vs. previous quarter
- 13F value
- $2.24B
- Reported value at the end of Q2 2023
- Superinvestors holding
- 0
- At the end of Q2 2023
Superinvestors holding KDNY, Q2 2023
No superinvestor reported holding KDNY at the end of Q2 2023.
Latest insider trades
Open-market purchases and sales by Chinook Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 1, 2023 (view filing) | Aug 1 | Same day | King Andrew JamesChief Scientific Officer | SSale | −1.17K | $39.03 | −$45.6K | −5.7%19.2K after | |
| May 31, 2023 (view filing) | May 30 | 1 day | Greenman William MarinerDirector | SSale | −1.16K | $23.30 | −$26.9K | −4.7%23.6K after | |
| Apr 26, 2023 (view filing)5:19 PM ET | Apr 24 | 2 days | Dobmeier EricPresident, CEO | SSale | −23.8K | $21.58 | −$513.5K | −7.3%302.3K after | |
| Apr 26, 2023 (view filing)5:19 PM ET | Apr 24 | 2 days | Dobmeier EricPresident, CEO | SSale | +1.20K | $22.26 | +$26.7K | +0.4%301.1K after | |
| Apr 19, 2023 (view filing) | Apr 17 | 2 days | Jerel DavisDirector | SSale | −295.8K | $20.75 | −$6.14M | −40.0%443.7K after | |
| Apr 5, 2023 (view filing)4:43 PM ET | Apr 3 | 2 days | King Andrew JamesChief Scientific Officer | SSale | −5.00K | $23.34 | −$116.7K | −22.7%17.0K after | 10b5-1 |
| Apr 4, 2023 (view filing) | Apr 4 | Same day | Krishnan MaheshDirector | SSale | −924 | $23.01 | −$21.3K | −42.0%1.27K after | 10b5-1 |
| Mar 3, 2023 (view filing) | Mar 1 | 2 days | Jerel DavisDirector | SSale | −400.0K | $22.75 | −$9.10M | −65.5%211.0K after | 3 lots |
| Feb 15, 2023 (view filing) | Feb 10 | 5 daysLate | Bjerkholt EricChief Financial Officer | SSale | −857 | $23.75 | −$20.4K | −2.2%38.9K after | |
| Feb 15, 2023 (view filing) | Feb 10 | 5 daysLate | Dobmeier EricPresident, CEO | SSale | −8.10K | $23.75 | −$192.3K | −2.6%301.1K after |
Top 10 13F holders, Q2 2023
The largest institutional positions in Chinook Therapeutics, Inc. at the end of Q2 2023; share changes are against Q1 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Samsara BioCapital, LLC | 5,161,888 | $198.3M | 34.81% | 00.0% | Unchanged |
| Frazier Life Sciences Management, L.P. | 4,345,559 | $167.0M | 9.97% | 00.0% | Unchanged |
| BlackRock Inc. | 4,263,241 | $163.8M | 0.00% | +320,702+8.1% | Added |
| Vanguard Group Inc | 2,948,165 | $113.3M | 0.00% | +100,330+3.5% | Added |
| State Street Corp | 2,907,317 | $111.7M | 0.01% | +219,269+8.2% | Added |
| Alpine Associates Management Inc. | 2,131,000 | $81.9M | 3.69% | +2,131,000 | New |
| Eventide Asset Management, LLC | 1,927,000 | $74.0M | 1.25% | +487,436+33.9% | Added |
| Suvretta Capital Management, LLC | 1,748,141 | $67.2M | 3.60% | +179,344+11.4% | Added |
| Farallon Capital Management, L.L.C. | 1,523,000 | $58.5M | 0.35% | +1,523,000 | New |
| Baker Bros. Advisors LP | 1,455,202 | $55.9M | 0.32% | 00.0% | Unchanged |